Edition:
United States

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

44.59USD
12:12pm EDT
Change (% chg)

$0.64 (+1.46%)
Prev Close
$43.95
Open
$43.92
Day's High
$44.66
Day's Low
$43.83
Volume
758,805
Avg. Vol
2,116,206
52-wk High
$45.84
52-wk Low
$36.76

Latest Key Developments (Source: Significant Developments)

Abbott reports CE Mark for tacticath contact force ablation catheter
Tuesday, 9 May 2017 09:00am EDT 

May 9 (Reuters) - Abbott Laboratories ::Abbott announces CE Mark for tacticath™ contact force ablation catheter, sensor enabled™.Abbott Laboratories - currently tacticath contact force ablation catheter is available in select markets in europe; full market release expected in q3.  Full Article

Abbott Laboratories develops 2 new science-based nutrition drinks for patients undergoing surgery
Wednesday, 26 Apr 2017 08:00am EDT 

April 26 (Reuters) - Abbott Laboratories ::Abbott Laboratories - developed two new science-based nutrition drinks for patients undergoing surgery.  Full Article

Abbott CFO says "We're not going to really be in a good position to give a lot of detailed guidance (on Alere) until minimum Q4" - Conf Call
Wednesday, 19 Apr 2017 10:41am EDT 

April 19 (Reuters) - Abbott Laboratories :Abbott CEO says "the acquisition of Alere will significantly expand our diagnostics presence and leadership in that space" - Conf Call.Abbott CEO says "the integration of St. Jude is going well and we're on track to achieve our projected synergy targets" - Conf Call.Abbott CEO says financial impact of Alere acquisition to be revealed at a later date - Conf Call.Abbott CEO says Q2 adjusted EPS forecast of $0.59 to $0.61 - Conf Call.Abbott CEO says "in nutrition, we now forecast low single-digit sales growth for both the second quarter and the full year" - Conf Call.Abbott CFO "look, the compay's (Alere) has had some challenges. We all know that and it's a bit of a fixer-upper and we know that, I'd say we're pleased to have the resolution of this matter behind us" - Conf Call.Abbott CFO says "We're not going to really be in a good position to give a lot of detailed guidance (on Alere) until minimum Q4" - Conf Call.Abbott CFO on warning letter: "Not going to change our launch dates or assumptions on approval dates because I don't see a reason to do that yet".Abbott CEO:"We still like the long term prospect of China (as it relates to the nutrition market)".Abbott Exec - Demonitization in India modestly impacted Abbott results. That impact is diminishing and will continue to diminish.Abbott Exec - With respect to India's goods and services tax, Abbott is monitoring that, because time line has been a "little bit fluid".  Full Article

Abbott Q1 adjusted earnings per share $0.48 from continuing operations
Wednesday, 19 Apr 2017 07:45am EDT 

April 19 (Reuters) - Abbott Laboratories ::Abbott reports first-quarter 2017 results.Q1 adjusted earnings per share $0.48 from continuing operations.Q1 GAAP earnings per share $0.22 from continuing operations.Q1 earnings per share view $0.43 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $2.40 to $2.50 from continuing operations.Q1 sales $6.3 billion versus I/B/E/S view $6.16 billion.Abbott Laboratories - Q1 worldwide sales of $6.3 billion increased 29.7 percent on a reported basis and 3.2 percent on a comparable operational basis.Q1 total nutrition sales $1,642 million, down 1.7 percent on reported basis.Abbott's full-year earnings-per-share guidance remains unchanged.Abbott Laboratories says q1 total pediatric sales $927 million, down 4.1 percent on a reported basis.Abbott Laboratories - Q1 total diagnostics sales $1,158 million, up 3.6 percent on a reported basis.Abbott Laboratories - Q1 total vascular sales $703 million, up 16.9 percent on a reported basis.Abbott-Integration of St. Jude going well, recently launched products contributing to double-digit sales growth across several areas of medical devices unit.  Full Article

Abbott Laboratories to buy Alere for $51 per share - FT, citing sources
Friday, 14 Apr 2017 03:08am EDT 

Abbott Laboratories : Abbott laboratories has ended protracted legal battle over its $5 bln plan to buy alere by agreeing to purchase smaller u.s. Rival at a lower price - FT .Abbott will pay $51 a share to acquire the diagnostic testing group instead of the earlier $56-a-share price - FT, citing sources.  Full Article

U.S. FDA says issued a warning letter to Abbott Laboratories
Thursday, 13 Apr 2017 10:15am EDT 

U.S. Food and Drug Administration : Says issued a warning letter to Abbott Laboratories . Says raises quality concerns after inspection of St. Jude's Sylmar facility .Says to Abbott failure to correct violations may result in regulatory action without further notice.  Full Article

FTC approves final order settling charges for Abbott's deal with St. Jude Medical
Thursday, 23 Feb 2017 01:18pm EST 

U.S. FTC: Approved final order settling charges that Abbott Laboratories’ $25 billion acquisition of St. Jude Medical would likely be anticompetitive .Abbott is required to notify FTC if it intends to buy lesion-assessing ablation catheter assets from Advanced Cardiac Therapeutics.  Full Article

Abbott Laboratories commences exchange offers, consent solicitations for St. Jude Medical notes
Tuesday, 21 Feb 2017 08:55am EST 

Abbott Laboratories :Abbott laboratories - Abbott commences exchange offers and consent solicitations for St. Jude Medical LLC notes.  Full Article

ABBOTT SETS QUARTERLY DIVIDEND OF $0.265 PER SHARE
Friday, 17 Feb 2017 11:25am EST 

Abbott :SETS QUARTERLY DIVIDEND OF $0.265 PER SHARE.  Full Article

European Commission clears Abbott acquisition of Alere
Wednesday, 25 Jan 2017 11:00am EST 

Alere Inc : European Commission clears Abbott acquisition of Alere .Alere inc - "We remain highly confident that merger will close according to terms of agreement" with Abbott.  Full Article

More From Around the Web

BRIEF-Abbott reports CE Mark for tacticath contact force ablation catheter

* Abbott announces CE Mark for tacticath™ contact force ablation catheter, sensor enabled™